Last reviewed · How we verify
Subcutaneous enoxaparin sodium
Enoxaparin sodium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin sodium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Prophylaxis of venous thromboembolism, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.
At a glance
| Generic name | Subcutaneous enoxaparin sodium |
|---|---|
| Also known as | Lovenox, experimental |
| Sponsor | Zhongshan Hospital (Xiamen), Fudan University |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Coagulation factors Xa and IIa (via antithrombin III enhancement) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Enoxaparin is derived from unfractionated heparin and works by potentiating antithrombin III, a natural anticoagulant. This leads to inactivation of coagulation factors Xa and IIa (thrombin), preventing thrombus formation. The subcutaneous formulation provides predictable pharmacokinetics and is used for both prophylaxis and treatment of thromboembolism.
Approved indications
- Prophylaxis of venous thromboembolism
- Treatment of acute deep vein thrombosis
- Treatment of acute pulmonary embolism
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
- Osteoporosis (with long-term use)
Key clinical trials
- A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (PHASE2)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration. (NA)
- Anticoagulation-free VV ECMO for Acute Respiratory Failure (PHASE2, PHASE3)
- A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA (PHASE2)
- Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery (NA)
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: